Stonepine Capital Management buys $26 Million stake in SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN) : Stonepine Capital Management scooped up 873,064 additional shares in SciClone Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 2,048,638 shares of SciClone Pharmaceuticals which is valued at $26 Million.SciClone Pharmaceuticals makes up approximately 32.56% of Stonepine Capital Management’s portfolio.

Other Hedge Funds, Including , Teacher Retirement System Of Texas boosted its stake in SCLN in the latest quarter, The investment management firm added 1,290 additional shares and now holds a total of 5,751 shares of SciClone Pharmaceuticals which is valued at $73,095.Matarin Capital Management reduced its stake in SCLN by selling 1,597 shares or 0.92% in the most recent quarter. The Hedge Fund company now holds 172,302 shares of SCLN which is valued at $2.2 Million. SciClone Pharmaceuticals makes up approx 0.31% of Matarin Capital Management’s portfolio.Lsv Asset Management boosted its stake in SCLN in the latest quarter, The investment management firm added 143,213 additional shares and now holds a total of 884,846 shares of SciClone Pharmaceuticals which is valued at $11.2 Million. SciClone Pharmaceuticals makes up approx 0.02% of Lsv Asset Management’s portfolio.Numeric Investors reduced its stake in SCLN by selling 150,016 shares or 13.77% in the most recent quarter. The Hedge Fund company now holds 939,741 shares of SCLN which is valued at $12.2 Million. SciClone Pharmaceuticals makes up approx 0.13% of Numeric Investors’s portfolio.State Board Of Administration Of Florida Retirement System reduced its stake in SCLN by selling 8,446 shares or 5.21% in the most recent quarter. The Hedge Fund company now holds 153,800 shares of SCLN which is valued at $2 Million. SciClone Pharmaceuticals makes up approx 0.01% of State Board Of Administration Of Florida Retirement System’s portfolio.

SciClone Pharmaceuticals closed down -0.21 points or -1.65% at $12.5 with 8,63,236 shares getting traded on Monday. Post opening the session at $12.73, the shares hit an intraday low of $11.935 and an intraday high of $12.96 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, SciClone Pharmaceuticals reported $0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.14 according to the earnings call on Nov 9, 2015. Analyst had a consensus of $0.12. The company had revenue of $42.90 million for the quarter, compared to analysts expectations of $40.61 million. The company’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.

SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments including China and the rest of the world (the United States and Hong Kong). The Company’s lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications and RapidFilm an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Leave a Reply

SciClone Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on SciClone Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.